BioLab Holdings Expands Placental Membrane Portfolio With New Membrane Wrap Amniotic Hydro
BioLab Holdings, Inc., a Phoenix-based medical technology company focused on tissue restoration, has expanded its portfolio of placental membrane products with the addition of Membrane Wrap™ Amniotic Hydro. The new product is a hydrated amnion membrane designed to provide protective coverage for acute and chronic wounds, further broadening the range of membrane configurations available to healthcare providers through BioLab Holdings and its distribution network.
The launch represents another step in BioLab’s strategy to build a comprehensive portfolio of placental membrane allografts while maintaining an emphasis on product quality, consistency and provider choice. Membrane Wrap Amniotic Hydro builds on the company’s existing hydrated amniotic membrane platform and introduces a dual-layer membrane configuration preserved in amniotic fluid derived from the same donor.
The new product joins BioLab’s established family of placental membrane offerings, which includes Membrane Wrap Lite™, Tri-Membrane Wrap™, Membrane Wrap™ and Membrane Wrap – Hydro™. Collectively, the portfolio is designed to provide healthcare providers with different membrane constructions, sizes and configurations that can be selected according to individual procedural requirements.
New Hydrated Amniotic Membrane Product
Membrane Wrap – Amniotic Hydro™ is an allogeneic dual-layer amniotic membrane protective cover. The membrane is hydrated and preserved in centrifuged and filtered amniotic fluid obtained from the same donor.
According to BioLab, the product is terminally sterilized using irradiation and is intended to function as a supportive barrier that provides protective coverage from the surrounding environment for both acute and chronic wounds.
The product is available in multiple sizes, ranging from 2 x 2 centimeters to 6 x 8 centimeters. The range is intended to give healthcare providers flexibility when selecting a membrane based on the size and requirements of the wound or procedure.
The addition of Membrane Wrap Amniotic Hydro expands the options available within BioLab’s hydrated membrane platform. By offering a dual-layer amniotic membrane in a hydrated and preserved format, the company is seeking to provide another configuration for clinicians who incorporate placental membrane products into wound-care procedures.
Placental tissues, including amniotic membranes, have been used in a variety of tissue-restoration and wound-management applications. These materials can serve as protective coverings, and their physical characteristics allow them to be incorporated into procedures where a biological membrane is required.
BioLab’s focus is on developing and supplying these tissue-based products while expanding the range of configurations available to providers.
Expanding a Broader Placental Membrane Portfolio
Membrane Wrap Amniotic Hydro becomes the latest addition to BioLab’s growing portfolio of placental membrane allografts.
The existing product family includes Membrane Wrap Lite™, Tri-Membrane Wrap™, Membrane Wrap™ and Membrane Wrap – Hydro™. Each product provides a different membrane construction or configuration, allowing providers to consider factors such as size and product format when determining which product best fits a particular procedure.
For medical technology companies serving wound-care providers, portfolio breadth can be an important consideration. Different procedures and wound presentations can require different physical characteristics or membrane configurations. BioLab’s expansion is intended to address this need by providing a broader selection rather than relying on a single product format.
Jaime Leija, President and CEO of BioLab Holdings, said healthcare providers have emphasized the importance of quality, consistency and choice when selecting placental membrane products.
According to Leija, the addition of Membrane Wrap Amniotic Hydro reflects BioLab’s commitment to building a trusted portfolio that provides providers with more options while maintaining the quality standards expected from the company.
The comments highlight the company’s approach to portfolio development: expanding product availability while maintaining consistency and quality across its placental membrane offerings.
Product Designed for Acute and Chronic Wounds
Membrane Wrap Amniotic Hydro is intended for use as a supportive barrier providing protective coverage from the surrounding environment for acute and chronic wounds.
Acute and chronic wounds can present different clinical challenges, and wound-care providers may require a range of products depending on the specific characteristics of a wound and the treatment setting. By introducing a new hydrated amniotic membrane configuration, BioLab is expanding its product options for providers working across these applications.
The new product’s dual-layer construction and hydrated preservation format are distinguishing features within the company’s portfolio. It is preserved in centrifuged and filtered amniotic fluid derived from the same donor, according to BioLab.
The company also states that the product undergoes terminal sterilization using irradiation. These processing and sterilization characteristics form part of the manufacturing and quality framework behind the product before it reaches healthcare providers.
The availability of multiple sizes, from 2 x 2 cm through 6 x 8 cm, further supports procedural flexibility.
AATB Accreditation Strengthens Quality Infrastructure
The launch of Membrane Wrap Amniotic Hydro follows another significant milestone for BioLab Holdings: the company’s recent accreditation by the Association for the Advancement of Tissue and Biologics (AATB).
The accreditation represents an important development for a company involved in tissue-based products. BioLab said the accreditation reflects adherence to rigorous standards covering areas including tissue handling, processing, storage and distribution.
For BioLab, the accreditation comes as the company continues expanding its placental membrane portfolio. The timing underscores the company’s stated focus on developing its product range alongside the quality systems and operational capabilities required to support that growth.
Christy Norman, Vice President of Quality at BioLab, described the AATB accreditation as an important foundation for the company’s next phase of development.
Norman said that as BioLab expands its portfolio, the company is simultaneously focused on strengthening the quality systems and operational capabilities supporting its products. She emphasized the importance of ensuring that healthcare providers have confidence not only in the membrane product they select but also in the organization responsible for producing and supporting it.
Quality and Operational Excellence Remain a Focus
The combination of the new product launch and AATB accreditation reflects BioLab’s efforts to develop its business around both portfolio expansion and quality infrastructure.
For tissue-based medical products, quality processes extend across multiple stages of the product lifecycle. Tissue handling, processing, preservation, storage and distribution all require appropriate controls and procedures. Accreditation can provide an external framework for evaluating those systems and demonstrating adherence to recognized industry standards.
BioLab’s leadership has positioned the recent accreditation as a foundation for future growth rather than simply a standalone milestone.
The company is continuing to expand its product portfolio while investing in the operational capabilities that support the products. This approach is particularly relevant as the number of membrane configurations available to healthcare providers increases.
Membrane Wrap Amniotic Hydro adds another option to that growing portfolio and gives BioLab an opportunity to extend its reach among providers seeking hydrated amniotic membrane products for wound-care applications.
Strengthening Provider Choice
A central theme of BioLab’s product strategy is provider choice. The company’s portfolio now includes multiple placental membrane products with different constructions and configurations.
The addition of Membrane Wrap Amniotic Hydro provides another option for healthcare professionals to consider based on procedural requirements. Its dual-layer structure, hydrated preservation format, donor-matched amniotic fluid preservation and range of available sizes distinguish it within the BioLab portfolio.
The company believes that maintaining a broad range of options can help providers select products according to the needs of individual procedures while maintaining consistent quality expectations.
This approach also allows BioLab to build on its existing expertise in hydrated amniotic membranes rather than introducing the new product as an isolated offering.
Commercial Availability
Membrane Wrap Amniotic Hydro is now available through BioLab Holdings and the company’s distribution network. The commercial launch means healthcare providers can access the new product alongside the company’s existing placental membrane portfolio.
The availability of the product marks the latest stage in BioLab’s effort to expand its presence in tissue restoration and wound-care technologies.
As the company moves forward, its portfolio strategy is being supported by the quality and operational infrastructure highlighted through its recent AATB accreditation. BioLab has indicated that portfolio expansion and quality-system development will continue in parallel as it works to meet the needs of healthcare providers.
The launch of Membrane Wrap Amniotic Hydro therefore represents more than the introduction of another membrane product. It demonstrates BioLab’s continuing effort to broaden its placental membrane platform, provide additional choices for healthcare professionals and strengthen the systems supporting its products.
With a portfolio that now includes Membrane Wrap Lite™, Tri-Membrane Wrap™, Membrane Wrap™, Membrane Wrap – Hydro™ and the newly introduced Membrane Wrap Amniotic Hydro™, BioLab is positioning itself to provide a wider range of tissue-restoration solutions.
The company will continue to focus on quality, consistency and operational excellence as it expands its offerings. For providers treating acute and chronic wounds, the addition of a hydrated, dual-layer amniotic membrane in multiple sizes provides another product configuration within BioLab’s growing portfolio.
BioLab Holdings is headquartered in Phoenix and remains focused on tissue restoration through its portfolio of placental membrane products. The company’s latest product is now commercially available through its distribution network, expanding access to its growing range of allograft solutions.
For more information, visit BioLab Holdings.
About BioLab Holdings, Inc.
BioLab Holdings, Inc. is a Phoenix-based medical technology company focused on advancing tissue restoration through innovation, strategic partnerships and commercialization. BioLab combines clinician-driven product strategy, entrepreneurial partnerships and rapid commercialization to identify, develop and deliver technologies across care settings.
BioLab’s subsidiaries, BLS Labs, LLC and BLS Sales & Marketing, LLC, are accredited by the Association for Advancing Tissue and Biologics (AATB), reflecting the organization’s commitment to rigorous standards for quality, safety and operational excellence.
BioLab’s placental membrane portfolio includes Membrane Wrap Lite™, Tri-Membrane Wrap™, Membrane Wrap™, Membrane Wrap – Hydro™ and Membrane Wrap™ Amniotic Hydro. The company’s broader wound care portfolio includes APIS®, a collagen-based wound matrix featuring Mānuka honey and hydroxyapatite; Microlyte®, a fully synthetic antimicrobial matrix; and Microlyte® PainGuard™, which combines Microlyte® technology with lidocaine HCl for local pain relief.